How does a fractional CRO build pipeline for a biotech company in 2027?

Direct Answer

A fractional CRO in biotech does not cold-call lab directors. Instead, they design a pipeline that mirrors the company’s clinical development cycle: pre-seed discovery, IND-enabling studies, Phase I/II trials, or commercial launch prep. The work involves mapping the buyer journey from principal investigator to procurement, building relationships with KOLs and CRO partners, and using data from platforms like Salesforce and Gong to track multi-month deal stages. The fractional CRO also sets up a revenue operations framework that connects marketing content (white papers, conference talks) to sales outreach, all while coaching a lean internal team. Expect to pay a monthly retainer that covers strategy, execution oversight, and 1-2 days of direct selling per week, with equity or bonuses reserved for pipeline milestones like signed LOIs or first revenue.

The Biotech Buyer in 2027: Why Pipeline Is Different

Biotech buyers in 2027 are not transactional. A principal investigator at a university medical center or a procurement officer at a large pharma company operates on timelines measured in quarters, not weeks. The fractional CRO must understand that the buying group includes the lab director, the grants administrator, the compliance officer, and often a legal team reviewing IP terms. Pipeline velocity is inherently slow, and pushing for a close before the clinical data is ready can kill the deal. The fractional CRO’s job is to build a forecastable, stage-gated pipeline that aligns with the company’s clinical milestones, not a generic sales funnel.

The key difference from SaaS or enterprise software: biotech sales are often tied to an annual grant cycle or a clinical trial start date. A fractional CRO must map the pipeline stages to these external events. For example, a company selling a novel assay kit might see its pipeline accelerate when a Phase II trial begins, because the principal investigator needs validated tools. The fractional CRO uses platforms like Clari to forecast these events and Gong to analyze call patterns with investigators, identifying when a deal is truly progressing versus stalled.

Step One: Map the Stakeholder and Decision Chain

Before any outreach, the fractional CRO documents every role that touches a purchase decision. In biotech, this often includes:

• Principal Investigator (PI) – the scientific lead who champions the product.
• Lab Manager – the operational buyer who cares about ease of use and training.
• Grants Officer or Procurement – controls budget and compliance.
• Legal/IP Counsel – reviews data usage and licensing terms.
• CRO Partner – if the PI outsources work, the CRO’s opinion matters.

The fractional CRO builds a stakeholder map in a CRM like Salesforce or HubSpot, tagging each contact with their role, influence level, and buying stage. They then design outreach sequences that address each role’s concerns. For example, a PI gets a data sheet on validation studies; the grants officer gets a pricing summary with compliance certifications. This is not a one-size-fits-all sequence. The fractional CRO sets up automated but customized sequences in Outreach or Salesloft, with triggers based on whether a contact opens a white paper or attends a webinar.

Step Two: Align Sales Stages to Clinical Milestones

A standard SaaS pipeline has stages like "demo," "proposal," and "negotiation." In biotech, the stages must reflect the reality of clinical development:

• Discovery – initial contact with PI or lab, often at a conference.
• Interest – PI requests data or a sample kit.
• Validation – PI runs internal tests or reviews published data (this can take 2-6 months).
• Budget Approval – grants officer or procurement signs off.
• Legal Review – IP and data use terms negotiated.
• Commitment – purchase order or contract signed.

The fractional CRO uses Clari or a custom Salesforce dashboard to track how many deals are in each stage and how long they stay there. They set up alerts for deals stuck in "Validation" for more than 90 days, prompting a call to the PI to understand delays. Pipeline reviews happen monthly, not weekly, because the cycle is longer. The fractional CRO also builds a leading indicator dashboard that tracks activities like white paper downloads, conference meeting requests, and CRO referrals, not just closed-won revenue.

Step Three: Use Content and Events to Attract Qualified Leads

Biotech buyers are skeptical of generic sales pitches. They trust published data, peer-reviewed studies, and conference presentations. The fractional CRO works with the CEO and scientific team to create content that demonstrates domain expertise: white papers on assay validation, case studies of successful IND filings, and webinars on regulatory pathways. This content is not marketing fluff – it must be technically accurate and cite real protocols.

The fractional CRO also identifies key conferences for the company’s niche: BIO International, ASCO, AACR, or smaller disease-specific meetings. They help the team prepare for these events by scheduling pre-meetings with targeted PIs, setting up demo stations, and following up within 48 hours with a personalized email that references the conversation. Post-conference follow-up is where most pipeline is built, because the PI is thinking about their next grant cycle.

Step Four: Build a Referral Network with CROs and KOLs

Biotech sales often happen through trusted intermediaries. A CRO (contract research organization) that runs a PI’s trial can recommend a tool or service. A KOL (key opinion leader) at a major medical center can influence dozens of labs. The fractional CRO actively builds these relationships by:

• Partnering with 2-3 CROs that serve the company’s therapeutic area, offering co-marketing or referral fees.
• Engaging KOLs through advisory boards or paid consulting roles, so they become advocates.
• Joining communities like Pavilion (joinpavilion.com) and RevOps Co-op to find other revenue leaders who have biotech contacts.

This network is the fractional CRO’s primary pipeline source. Cold outreach has a lower conversion rate in biotech because the buyer’s trust threshold is high. A referral from a CRO or KOL can cut the sales cycle by months, because the PI already has a relationship with the referrer.

Step Five: Set Up Revenue Operations for Long Cycles

Biotech pipeline data is often messy. The fractional CRO implements a revenue operations framework that ensures every lead is tracked from first touch to close. This includes:

• CRM hygiene – deduplicating contacts, standardizing stage names, and tagging leads by therapeutic area.
• Lead scoring – weighting leads by role (PI scores higher than lab manager), engagement (downloaded a white paper), and timeline (upcoming grant cycle).
• Automated nurture sequences – sending relevant content every 30-60 days, not weekly, to avoid overwhelming the buyer.
• Forecasting – using Clari or a custom model that accounts for the probability of deals moving through clinical milestones.

The fractional CRO also trains the internal team on how to enter data consistently. Without clean data, the pipeline is a black box, and the CEO cannot make informed decisions about hiring or fundraising.

Step Six: Coach the Internal Team

Most biotech founders are scientists, not salespeople. They may have a small BD team that knows the science but not the mechanics of pipeline building. The fractional CRO coaches the team on:

• How to run a discovery call that focuses on the PI’s research goals, not the product features.
• How to handle objections about pricing, validation, or regulatory risk.
• How to use the CRM to log activities and update stages.
• How to manage long-cycle relationships without burning out.

The fractional CRO also models the behavior they want to see. They join 1-2 calls per week with the team, demonstrate the technique, and then debrief. Over 3-6 months, the team becomes self-sufficient, and the fractional CRO can reduce their hours or transition to a strategic advisory role.

FAQ

How is a fractional CRO different from a full-time VP of Sales in biotech? A fractional CRO works 8-12 days per month, costs less, and brings a network of CRO and KOL contacts. A full-time VP of Sales costs more and is better for companies that need daily leadership and a large internal team. The choice depends on your stage: pre-revenue biotech often benefits from fractional, while post-revenue companies with a sales team may need full-time.

Can a fractional CRO work remotely for a biotech company? Yes, most fractional CROs work remote or hybrid. Biotech buyers are often at universities or hospitals, so in-person visits are valuable but not required daily. The fractional CRO should travel to key conferences and 1-2 on-site meetings per quarter. Local supply of biotech-experienced fractional CROs is thin in most regions, so remote is common.

What metrics should I track to evaluate the fractional CRO’s pipeline building? Track qualified leads in stage 2+ (validation or budget approval), pipeline value weighted by probability, and time-to-close for deals that reach commitment. Do not expect high volume in the first 3 months. The key leading indicator is the number of CRO and KOL referrals, not cold outreach replies.

How do I pay a fractional CRO in biotech? Monthly retainer of $8k-$25k for 8-12 days of work, plus 0.5-1.5% equity for early-stage companies or a performance bonus (e.g., $5k-$15k per signed LOI or first revenue deal) for later-stage firms. Cash compensation is higher if the company has funding; equity is more common in pre-revenue ventures.

What if my biotech company has no clinical data yet? Pipeline building will focus on investor relations, partnership development, and pre-seed research collaborations. The fractional CRO can help you identify CROs and academic labs for pilot studies, but direct sales will not happen until you have validation data. Set expectations with investors accordingly.

Sources

• Pavilion – Revenue Leadership Community
• RevOps Co-op – Operations Community
• Harvard Business Review – Sales Strategy
• First Round Review – Startup Sales
• SaaStr – Revenue Leadership
• LinkedIn – Sales & Biotech Groups

People also search for: fractional cro biotech company · hire a fractional cro for biotech company · biotech company fractional cro · fractional cro near me